Protein kinase R-like endoplasmic reticulum kinase (PERK, also known as EIF2AK3 or PEK) is a type I transmembrane protein kinase localized to the ER membrane. As one of the three major sensors of the unfolded protein response (UPR), PERK couples ER stress to translational attenuation through phosphorylation of eIF2α at Ser51[@harding2000].
PERK activation represents a critical adaptive mechanism during protein misfolding stress, but chronic PERK signaling contributes to neurodegeneration in Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and prion disorders[@mercado2020].
¶ Structure and Domains
PERK contains:
- N-terminal luminal domain (1-576): Senses misfolded proteins in the ER lumen; interacts with BiP/GRP78
- Transmembrane domain (577-597): Anchors PERK to ER membrane
- Cytosolic kinase domain (666-1114): Serine/threonine kinase activity; phosphorylates eIF2α
Activation mechanism: Under normal conditions, BiP binds the luminal domain, maintaining PERK monomeric and inactive. ER stress causes BiP release, allowing PERK dimerization, trans-autophosphorylation, and activation[@carrara2015].
PERK is one of three ER stress sensors (along with IRE1 and ATF6):
- Stress sensing: Accumulation of unfolded proteins in the ER lumen
- BiP release: Competition between misfolded proteins and PERK for BiP binding
- Dimerization: Luminal domains interact, bringing kinase domains together
- Autophosphorylation: Trans-phosphorylation at activation loop residues
- eIF2α phosphorylation: Converts eIF2α to a potent inhibitor of eIF2B
PERK is one of four eIF2α kinases (with GCN2, PKR, HRI), integrating diverse stress signals into a common translational response[@wek2006]:
- Global translation inhibition: Reduces protein load on stressed ER
- Selective ATF4 translation: Activates stress-adaptive gene expression
- Redox homeostasis: ATF4 induces antioxidant genes
- Amino acid metabolism: Upregulates amino acid transporters and biosynthesis
- Pancreatic β-cells: Essential for high secretory demand
- Plasma cells: Supports antibody production
- Osteoblasts: Bone matrix secretion
- Development: PERK mutations cause Wolcott-Rallison syndrome
In AD, PERK activation occurs early and intensifies with disease progression[@hoozemans2005]:
- Aβ oligomers: Activate PERK in cultured neurons
- Tau aggregates: Trigger ER stress and PERK activation
- Hippocampal neurons: Elevated p-PERK and p-eIF2α in AD brains
- BACE1 paradox: PERK signaling increases BACE1 translation via uORF bypass, accelerating Aβ production
- Synaptic dysfunction: Impaired LTP and memory consolidation
Evidence: Post-mortem AD brains show p-PERK immunoreactivity in neurons with neurofibrillary tangles[@hoozemans2007].
- α-synuclein: Overexpression or aggregation activates PERK
- Dopaminergic vulnerability: Substantia nigra neurons show elevated p-PERK
- MPTP models: PERK activation in nigrostriatal pathway
- LRRK2: Pathogenic variants may enhance ER stress susceptibility
Clinical correlation: p-PERK levels correlate with Lewy body density in PD patients[@baek2022].
- PolyQ-expanded huntingtin: Disrupts ER calcium homeostasis
- UPR activation: Chronic PERK signaling in striatal neurons
- R6/2 and HD-N171-82Q models: Elevated p-PERK and p-eIF2α
- Synaptic defects: Impaired dendritic protein synthesis
¶ ALS and FTD
- SOD1 mutations: Mutant SOD1 activates PERK in motor neurons
- TDP-43: Cytoplasmic aggregates trigger ER stress
- C9orf72: Dipeptide repeat proteins activate PERK
- FUS: Mutant FUS induces UPR activation
- PrP^Sc accumulation: Activates all three UPR branches
- PERK dependency: Genetic PERK reduction delays prion disease
- Therapeutic window: PERK inhibition after symptom onset still effective in mice
GSK2606414:
- Potent and selective PERK inhibitor (IC50 = 0.4 nM)
- Neuroprotective in prion disease models
- Extended survival in tauopathy mice
- Limitation: Pancreatic toxicity from β-cell dysfunction
GSK2656157:
- Improved brain penetration
- Reduced pancreatic toxicity at neuroprotective doses
- Protective in 5xFAD Alzheimer's model[@gsk2021]
AMG44:
- Next-generation PERK inhibitor
- Improved therapeutic window
Rather than inhibiting PERK directly, ISRIB stabilizes eIF2B to counteract p-eIF2α-mediated translational inhibition[@sidrauski2015]:
- Downstream of PERK
- Restores translation without affecting PERK signaling
- Neuroprotective in multiple neurodegeneration models
- Cognitive enhancement in healthy animals
- PERK heterozygosity: Reduces neurodegeneration in mouse models
- Conditional knockout: Temporal control to avoid developmental effects
- RNA interference: Reduce PERK expression in vulnerable neurons
| Interactor |
Relationship |
Disease Relevance |
| BiP/GRP78 |
Inhibitory binding partner |
ER stress sensing |
| eIF2α |
Phosphorylation substrate |
Translation control |
| ATF4 |
Downstream transcription factor |
Stress response |
| CHOP |
ATF4 target |
Apoptosis |
| GADD34 |
Phosphatase regulator |
Feedback loop |
| Nrf2 |
PERK phosphorylates |
Antioxidant response |
| FoxO1 |
PERK phosphorylates |
Metabolic regulation |
- Harding HP et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000;6(5):1099-1108, https://doi.org/10.1016/S1097-2765(00)00108-8 (2000)
- Mercado G et al. ER stress and neurodegeneration: Pathogenic mechanisms and therapeutic opportunities. Curr Top Med Chem. 2020;20(18):1621-1652, https://doi.org/10.2174/1568026620666200416092946 (2020))
- Carrara G et al. Characterization of the unfolded protein response in mammalian cells. Methods Mol Biol. 2015;1292:37-49, https://doi.org/10.1007/978-1-4939-2522-3_4 (2015))
- Wek RC et al. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans. 2006;34(Pt 1):7-11, https://doi.org/10.1042/BST20060007 (2006))
- Hoozemans JJM et al. The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol. 2005;110(2):165-172, https://doi.org/10.1007/s00401-005-1038-0 (2005))
- Hoozemans JJM et al. Activation of the unfolded protein response in Parkinson's disease. Biochem Biophys Res Commun. 2007;354(3):707-711, https://doi.org/10.1016/j.bbrc.2006.12.169 (2007))
- Baek JH et al. The PERK signaling pathway in Alzheimer's and Parkinson's disease. Front Neurosci. 2022;16:984844, https://doi.org/10.3389/fnins.2022.984844 (2022))
- GSK2656157 clinical development, https://doi.org/10.1016/j.ymthe.2021.05.014 (2021))
- Sidrauski C et al. Pharmacological dimerization and blockade of the integrated stress response. Cell. 2015;162(2):446-460, https://doi.org/10.1016/j.cell.2015.06.044 (2015))